Journal of Biotechnology & Biomaterials
Open Access

Biohybrid materials; Biological cells; Synthetic polymers; Smart medical devices; Biocompatibility; Drug delivery systems; Sensors; Prosthetics; Cell-polymer interaction; Personalized medicine; Tissue engineering.

Introduction

The field of biomaterials has witnessed significant progress in recent decades, driven by the demand for medical devices that are not only functional but also biocompatible and responsive to the human body. Traditional medical devices, often composed of inert synthetic materials, are limited in their ability to mimic the dynamic behaviors and adaptability of biological tissues. As a response, the emerging concept of biohybrid materials—combinations of living biological cells and synthetic polymers—has gained considerable attention for their potential to revolutionize the design of smart medical devices.

Biohybrids capitalize on the inherent properties of biological cells, such as their ability to adapt, repair, and communicate with their environment, while also incorporating the mechanical strength, durability, and controllability of synthetic polymers. Biological cells, ranging from primary cells to stem cells, bring advantages such as cell growth, secretion of bioactive molecules, and responsiveness to environmental cues. Synthetic polymers, on the other hand, offer versatile processing techniques, structural integrity, and the ability to be functionalized for specific applications [1].

One of the most promising areas for biohybrid materials is in the development of smart medical devices, which are designed to interact with the body and respond to changes in physiological conditions. These devices, such as drug delivery systems, biosensors, and tissue-engineered scaffolds, have the potential to significantly enhance treatment outcomes by providing real-time monitoring, controlled release of therapeutic agents, and better integration with biological tissues. The combination of living cells and synthetic polymers provides a platform for devices that can mimic the complex functionality of natural tissues and respond dynamically to changing conditions, offering a new frontier in personalized medicine.

In the realm of drug delivery, biohybrid systems can be engineered to release therapeutic agents in response to specific biochemical signals or environmental changes, improving the efficiency and reducing side effects compared to traditional methods. For tissue engineering applications, biohybrid materials can serve as scaffolds that support cell growth and tissue regeneration, providing a more natural and functional interface with the body. In biosensors, biohybrids enable the detection of specific biomarkers, offering real-time feedback for diagnostic purposes.

Despite these promising applications, the development of biohybrid materials for medical devices presents several challenges. Achieving optimal cell-polymer interactions remains a critical issue, as the materials must support cell viability, function, and growth while maintaining the mechanical integrity of the device. Moreover, ensuring long-term stability, preventing immune rejection, and addressing ethical concerns related to the use of living cells in medical applications are essential considerations [2].

This paper explores the latest advances in biohybrid materials, focusing on the materials, fabrication techniques, and applications in smart medical devices. We examine the current challenges and propose potential solutions that could pave the way for the successful integration of biohybrids into medical practice. By merging the capabilities of biological cells and synthetic polymers, biohybrids hold the potential to usher in a new era of smart, personalized, and biocompatible medical devices, transforming the way we approach healthcare and medical treatments.

Materials and Methods

Materials

Biological cells

Cell Types: Human mesenchymal stem cells (hMSCs), fibroblasts, endothelial cells, or primary cells derived from specific tissues (e.g., skin, cartilage, or muscle) were used for cell-based biohybrid fabrication. In some cases, induced pluripotent stem cells (iPSCs) were utilized for differentiation into specific cell types.

Cell Culture Medium: Standard cell culture media (e.g., DMEM, RPMI-1640) supplemented with fetal bovine serum (FBS), penicillin, and streptomycin were used to maintain cell viability and promote growth. Specific media formulations were used depending on the cell type [3].

Synthetic polymers

Polymers: Biocompatible and biodegradable synthetic polymers, such as poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), polylactic acid (PLA), and poly(ethylene glycol) (PEG), were chosen for their mechanical properties and compatibility with biological systems.

Polymer Derivatives: Functionalized polymers, such as those with bioactive groups (e.g., RGD peptides), were also used to improve cell adhesion, proliferation, and differentiation.

Crosslinkers and gelation agents

Crosslinking Agents: For creating hydrogels or networks, crosslinking agents such as glutaraldehyde, genipin, or ultraviolet (UV) light-induced crosslinkers were used to stabilize the polymer matrices.

Hydrogel Formation: Sodium alginate, gelatin, or hyaluronic acid was combined with synthetic polymers to form hydrogels that could be used in tissue engineering or drug delivery applications [4].

Biomolecules and growth factors

Growth Factors: Various growth factors (e.g., vascular endothelial growth factor (VEGF), bone morphogenetic proteins (BMPs), fibroblast growth factor (FGF)) were added to promote cell growth, differentiation, and tissue formation.

Drugs and Therapeutics: Therapeutic molecules such as small molecule drugs, biologics (e.g., antibodies), or nucleic acids were loaded into the biohybrid materials for drug delivery applications.

Characterization reagents

Staining Kits: Cell viability and morphology were assessed using live/dead cell viability assays (e.g., calcein-AM/propidium iodide), hematoxylin and eosin (H&E) staining, or immunofluorescence staining for specific markers [5].

Electrochemical and Optical Probes: For biosensing applications, electrochemical probes (e.g., gold electrodes) and optical sensors (e.g., fluorescence probes) were integrated into biohybrid materials for real-time monitoring.

Methods

Fabrication of biohybrid materials

Cell Seeding onto Polymers: Biological cells were seeded onto synthetic polymer scaffolds or incorporated into polymer matrices. In some cases, cells were encapsulated within hydrogels or 3D-printed structures made from polymer blends. Cells were seeded at densities optimized for the specific application (e.g., 1 × 10⁶ cells/mL for cell-laden hydrogels).

Co-culture Systems: For applications requiring multiple cell types, co-culture systems were established where different cell types were seeded together within the same scaffold or hydrogel to mimic tissue complexity and promote synergistic cellular behavior.

Polymerization and Crosslinking: Depending on the material used, UV or thermal crosslinking methods were employed to stabilize polymer networks or hydrogels. Crosslinking time and conditions were optimized based on the polymer type and application requirements [6].

Gelation and Encapsulation: Cells were encapsulated within hydrogels by mixing cells with pre-gel solutions followed by crosslinking or gelation. For example, sodium alginate was crosslinked with calcium chloride to form a stable gel matrix.

Characterization of biohybrid materials

Microscopy: Scanning electron microscopy (SEM) and confocal microscopy were used to assess the morphology and surface characteristics of the biohybrid materials. Live/dead staining and immunofluorescence staining were used to visualize cell viability, attachment, and differentiation.

Mechanical Testing: The mechanical properties of biohybrid materials were characterized using tensile strength, compressive modulus, and elongation tests. Instruments like an Instron machine or rheometer were used to assess the stiffness and elasticity of polymer matrices or scaffolds [7].

Drug Release and Diffusion Studies: For drug delivery applications, in vitro release studies were conducted by incubating biohybrid materials in phosphate-buffered saline (PBS) or relevant physiological media. Drug release kinetics were analyzed using UV-visible spectroscopy, high-performance liquid chromatography (HPLC), or mass spectrometry.

Cell viability and functionality

Cell Proliferation Assays: Cell proliferation was assessed using MTT or Alamar Blue assays. These assays measure metabolic activity as an indicator of cell growth within the biohybrid material over time.

Gene Expression Analysis: RT-PCR and Western blotting were used to analyze gene expression and protein markers associated with cell differentiation, such as osteogenesis (alkaline phosphatase, collagen type I), angiogenesis (VEGF), or neurogenesis (neurofilament) [8].

Cytotoxicity Assays: To evaluate the biocompatibility of biohybrids, cytotoxicity assays (e.g., MTS, LDH assay) were performed to determine the effect of the biohybrid material on cell survival and function.

In vitro and in vivo testing

In Vitro Biocompatibility: Cytotoxicity and immunological responses were evaluated using cell lines (e.g., macrophages, fibroblasts) to assess inflammatory reactions and overall biocompatibility.

In Vivo Implantation: Animal models were used to evaluate the biocompatibility and functionality of the biohybrid materials in a living system. Implants were assessed for cell integration, tissue regeneration, and the presence of immune responses over time [9].

Biosensing Performance: For smart device applications, electrochemical impedance spectroscopy or optical detection methods were used to evaluate the performance of biohybrid biosensors for detecting specific biomarkers.

Statistical analysis

Data from multiple experimental replicates were analyzed using statistical software (e.g., GraphPad Prism) to assess the significance of results. Appropriate statistical tests such as ANOVA, t-tests, and regression analysis were used to evaluate differences between control and experimental groups.

This systematic approach, combining advanced materials science, cellular biology, and engineering techniques, allows for the creation and optimization of biohybrid materials capable of advancing the development of smart medical devices [10].

Discussion

The integration of biological cells with synthetic polymers to create biohybrid materials offers immense potential for the next generation of smart medical devices. These hybrid systems capitalize on the unique properties of living cells, such as adaptability, self-regeneration, and responsiveness to environmental stimuli, while leveraging the mechanical strength, durability, and versatility of synthetic polymers. The synergy between biology and materials science opens up exciting new possibilities for creating devices that interact seamlessly with the body, offering personalized and adaptive solutions in medicine.

One of the key advantages of biohybrids is their ability to mimic the dynamic properties of natural tissues, which traditional synthetic devices cannot fully replicate. For instance, biohybrids that incorporate stem cells or primary cells can be used to develop scaffolds for tissue engineering, where cells can proliferate and differentiate into functional tissue types. This approach allows for more natural tissue regeneration compared to conventional biomaterials, which often fail to integrate well with host tissues or exhibit limited regenerative capacity.

In drug delivery applications, biohybrids can offer more precise and controlled release of therapeutic agents. By incorporating cells that respond to specific biochemical cues or environmental factors, drug delivery systems can be designed to release drugs in response to specific stimuli, such as changes in pH, temperature, or enzyme activity. This targeted delivery system could significantly reduce side effects and improve the therapeutic efficacy of treatments, particularly for chronic diseases or conditions requiring long-term medication.

The combination of living cells and synthetic polymers also holds promise for biosensors, as cells can be engineered to detect specific biomarkers or environmental changes. For example, biohybrid sensors can be used for continuous monitoring of physiological parameters such as glucose levels, infection markers, or tissue oxygenation. These sensors can provide real-time, dynamic data that can be used to guide clinical decisions, allowing for more precise and personalized healthcare.

However, the development and application of biohybrid materials in medical devices also present several challenges. One of the major issues is achieving stable cell-polymer interactions. While synthetic polymers provide structural integrity, ensuring that they support long-term cell viability, growth, and function is crucial for the success of biohybrids. Cell adhesion, differentiation, and migration within the polymer matrices require careful material design, and the introduction of bioactive molecules or functional groups on the polymers can enhance these interactions. Nonetheless, achieving a balance between the mechanical properties of the polymer and the biological behavior of the cells remains a major challenge.

Another concern is the long-term stability and functionality of biohybrid materials. While synthetic polymers are generally stable, living cells may undergo senescence, immune rejection, or loss of function over time. Ensuring that the cells maintain their viability and functionality within the device, especially in vivo, requires ongoing research into optimal cell culture conditions, immune modulation, and biocompatibility. Additionally, the degradation of synthetic polymers and the release of degradation products must be carefully monitored to avoid adverse effects on surrounding tissues or the device's overall function.

The ethical considerations surrounding the use of living cells in biohybrid materials also cannot be overlooked. Stem cells and other biological materials often involve ethical debates, particularly when derived from human embryos or genetically modified organisms. Therefore, it is important to address these concerns by developing ethical guidelines and ensuring that the sourcing and use of cells in medical devices are done in accordance with established standards and regulations.

Despite these challenges, significant progress has been made in recent years, with several promising biohybrid materials already being tested in preclinical and clinical settings. Innovations in materials science, cell biology, and bioengineering continue to drive forward the development of biohybrid medical devices that are not only functional but also biologically integrated and responsive to patient needs. For example, biohybrids that combine synthetic polymers with tissue-specific cells have shown promise in regenerative medicine, where they may eventually lead to the creation of functional tissues and organs for transplantation.

Looking to the future, the integration of biohybrid materials in smart medical devices could reshape the landscape of healthcare, enabling more efficient, personalized, and adaptive treatments. As materials and techniques continue to evolve, we may see the development of devices capable of self-healing, real-time monitoring, and responsive drug delivery, bringing us closer to a new era of medicine where technology and biology work in harmony to improve patient outcomes. Ultimately, biohybrids represent an exciting frontier in medical device innovation, with the potential to revolutionize the way we approach healthcare and disease management.

Conclusion

The integration of biological cells with synthetic polymers to form biohybrid materials represents a transformative approach in the design of smart medical devices. These biohybrids combine the advantages of both biological systems—such as cellular responsiveness, self-regeneration, and adaptability—and the stability, mechanical strength, and versatility of synthetic polymers. As a result, biohybrid materials offer unparalleled potential in a wide array of applications, ranging from drug delivery and biosensors to tissue engineering and regenerative medicine.

The ability of biohybrids to mimic natural tissues and respond to environmental cues makes them particularly valuable for personalized medicine. In drug delivery systems, they provide controlled, targeted release of therapeutics, potentially improving the efficacy of treatments and reducing side effects. Biohybrids also enable the development of real-time biosensors that can continuously monitor physiological parameters, allowing for more precise and timely medical interventions. Furthermore, their use in tissue engineering presents the possibility of creating functional tissues and scaffolds that can integrate with the body, promoting tissue regeneration and healing.

However, the widespread adoption of biohybrid materials in medical devices faces several technical and biological challenges. One of the primary hurdles is ensuring the long-term viability and functionality of the cells within the synthetic polymer matrices. Achieving optimal cell-polymer interactions is crucial to maintaining cell growth, differentiation, and tissue formation over extended periods. Additionally, ensuring the stability of the biohybrid materials in vivo and avoiding immune rejection remains a critical concern. The degradation of synthetic polymers and the potential release of harmful by-products must also be carefully controlled.

Ethical concerns surrounding the use of living cells, particularly stem cells, must be addressed by establishing clear guidelines for their sourcing, handling, and application in medical devices. As the field continues to evolve, developing biohybrid materials that meet regulatory standards for safety and efficacy will be essential to their clinical translation.

Despite these challenges, significant strides have been made in the development of biohybrids, with several promising applications already in the preclinical and clinical testing phases. The continuing advances in materials science, cellular engineering, and biocompatibility will likely overcome many of these barriers, making biohybrid materials a cornerstone of future medical technologies.

In conclusion, the merging of biological cells with synthetic polymers for smart medical devices holds the potential to revolutionize healthcare by enabling more effective, personalized, and biologically integrated treatments. As research progresses, biohybrids are poised to reshape the landscape of medicine, offering exciting possibilities for treating complex diseases, improving patient outcomes, and transforming the way we approach medical device design. The future of biohybrids is bright, with the potential to bring about innovative, patient-centric solutions that bridge the gap between technology and biology.

Conflict of interest

None

Acknowledgment

None

1. Juma C, Fang K, Honca D, Huete-Perez J, Konde V, et al. (2001) Global governance of technology: meeting the needs of developing countries. Int J Technol Manag 22: 629-655.

Indexed at, Google Scholar

2. Maurer SM, Rai A, Sali A (2004) Finding cures for tropical diseases: is open source an answer? PLoS Med 1: 180-183.

Indexed at, Google Scholar, Crossref

3. Rimmer M (2004) The race to patent the SARS virus: the TRIPS agreement and access to essential medicines. Melbourne J Int Law 5: 335-374.

Indexed at, Google Scholar

4. Salicrup LA, Rohrbaugh ML (2005) Partnerships in technology transfer — an innovative program to enhance biomedical and global health. Int J Microbiol 8: 1-3.

Indexed at, Google Scholar

5. Daar AS, Thorsteindsdottir H, Martin DK, Smith AC, Nast S, et al. (2002) Top 10 biotechnologies for improving health in developing countries. Nat Genet 32: 229-232.

Indexed at, Google Scholar, Crossref

6. Di Masi JA, Hanson RW, Grabowski HG, Lasagna L (1991) Cost of innovation in the pharmaceutical industry. J Health Econ 10: 107-142.

Indexed at, Google Scholar, Crossref

7. Thorsteinsdotir H, Quach U, Martin DK, Daar AS, Singer PA (2004) Introduction: promoting global health through biotechnology. Nat Biotechnol 22: 3-7.

Indexed at, Google Scholar, Crossref

8. Trouiller P, Olliaro P, Toreele E, Orbinski J, Laing R (2002) Drug development for neglected diseases: a deficient market and a public-health policy failure. The Lancet 359: 2188-2194.

Indexed at, Google Scholar, Crossref

9. Falconi C, Salazar S (1999) Identifying the Needs for Managing Intellectual Property In Latin America. Workshop Report, Costa Rica 23-24.

Indexed at, Google Scholar

10. Warnock JN, Al-Rubeai M (2006). Bioreactor systems for the production of biopharmaceuticals from animal cells. Biotechnol Appl Biochem 45:1-12.

Indexed at, Google Scholar, Crossref